7:30 am
Registration & Welcome Coffee

8:30 am Chair’s Opening Remarks

  • Shaker Mousa Professor ACPHS and Co-Founder, Nano-Pharmaceuticals

Structural Biology & Medicinal Chemistry for Drug Development

8:40 am Agonist Mechanisms to Address the Treatment Paradigm

Synopsis

  • Most integrin-targeted candidates use antagonist mechanisms
  • Explore the potential of positive regulation on integrins
  • Assess the benefits of this compared to antagonists

9:10 am Targeting Integrin Signaling

Synopsis

  • Evaluate this novel approach to specific targeting of integrin signaling
  • Avoid downstream cascades by blocking on specific signals
  • Define the potential of this method to avoid off-target immune response

9:40 am Panel Discussion: Genesis of 7 Hills Pharma & Translation of Integrin Agonist into the Clinic

Synopsis

  • Translating Biology into Clinic – potential clinical indications (augmenting infectious disease vaccination and solid tumor immunity)
  • Why have there been limited development of integrin agonists? Safety and efficacy?
  • The game changer? What data gives us the confidence of this approach?

10:15 am
Speed Networking & Morning Break

Synopsis

This session is the ideal opportunity to network and forge meaningful business relationships with many of the brightest minds working in the Integrin field, face to-face for the first time

11:00 am Utilizing Vascular Integrins as a Therapeutic Target for Acute & Long-COVID

Synopsis

  • Vascular integrins including alpha5beta1 and alphavbeta3 are experimentally validated receptors for SARS-CoV-2
  • Acute blockade of these integrins with clinically validated inhibitors can reduce SARS-CoV-2 infection
  • Chronic blockade of these integrins may also be therapeutic in cerebrovascular manifestations of long-COVID

11:30 am New Structural Insights into the Basis of Integrin-Ligand Interactions

Synopsis

  • Structure-based analysis of integrin function using single particle cryoelectron microscopy (Cryo-EM)
  • Structural dynamics of ligand-receptor interactions
  • Using cryo-EM for therapeutic antibody development

12:00 pm Roundtable Discussion:Specific v Pan Inhibition of Integrins

Synopsis

  • Integrin targets are very widely expressed
  • Define specificity early on to ensure off-target effects are minimized down-stream
  • Assess the advantages and disadvantages of specific versus pan inhibition of integrins
  • Discuss with your peers in this roundtable discussion, grouped by disease indication
  • Down stream adaptor proteins

1:00 pm
Lunch Break

Preclinical Development in Intergrin Binding & Targeting

2:00 pm Reprograming the immunosuppressive tumour microenvironment with selective integrin inhibition

  • Scott Turner Senior Vice President of Research, Pliant Therapeutics

Synopsis

  • Inhibition of avb8 and avb1 promotes ifng and suppresses tgfb signalling in tumors
  • Reprograming tumor cytokine levels promotes proinflammatory cell infiltration and suppress stromal protein synthesis
  • Treatment was synergistic with checkpoint inhibitors in multiple murine tumor models

2:30 pm Immune-Mediated Effects of the Integrin avb8 Inhibitors to Enhance Antitumor Efficacy

  • Natalia Blanco Associate Director, Immuo-Oncology, Morphic Therapeutics

Synopsis

  • Activation of TGF-β by αvβ8-expressing cells enhances tumor tolerance
  • αvβ8 inhibition is sufficient to reverse TGF-β-driven immunosuppression
  • αvβ8 inhibition on tumor and/or immune cells impairs regulatory mechanisms while unleashing a potent antitumor immunity

3:00 pm
Afternoon Refreshment & Networking

3:30 pm An Integrated & FAIR Data Ecosystem to Accelerate Integrin-based Research

Synopsis

  • Integrin targets are widely expressed across Gene Expression Studies, Drug Screening experiments, and more. However, this data landscape is highly fragmented.
  • Available studies are located in isolated public or proprietary sources that employ different syntaxes, schemas, entity notations, and metadata standards.
  • In summary, the datasets are not easily Findable, Available, Interoperable, or Reusable. Significant technical and logistical challenges pile up while integrating and analyzing these data.
  • Using a data-centric infrastructure, Elucidata’s Polly provides researchers with intuitive data access, FAIR data management, reproducible data processing workflows, and secure data storage.
  • This session will demonstrate how clean and linked integrin-specific data from public repositories or proprietary experiments can be accessed on Polly’s Enterprise Atlas. Researchers can leverage Polly’s capabilities to mine for novel associations from diverse sources and enhance the quality of their hypotheses.

3:40 pm Delving into the Thyrointegrin Antagonist & Cancer Therapeutics

  • Shaker Mousa Professor ACPHS and Co-Founder, Nano-Pharmaceuticals

Synopsis

  • Considering the challenges in developing novel strategies and the failure of previous avb3 antagonists in cancer therapy
  • Pinpoint the problems with these in order to re-assess the MoAs
  • Overcome these challenges to design novel therapeutics

4:10 pm Development of OTT166 an RGD-Binding Integrin Antagonist for the Topical Treatment of Diabetic Retinopathy

  • Scott Edwards Chief Development Operating Officer, OcuTerra Therapeutics

Synopsis

  • Distributes to posterior segment of the eye after eye drop administration
  • Reduces neovascularization and vessel leakage in multiple animal models of diabetic retinopathy and wet-AMD
  • Phase 1 clinical data show safety and tolerability and evidence of biological activity – proceeding to Phase 2

4:40 pm
Chair’s Closing Remarks & End of Conference Day One

  • Shaker Mousa Professor ACPHS and Co-Founder, Nano-Pharmaceuticals